The Food and Drug Administration (FDA) has approved Penmenvy (meningococcal Groups A, B, C, W, and Y vaccine ... NHBA, and OMV). Noninferiority was observed with Penmenvy vs 2 doses of Bexsero ...

funding to further develop a prophylactic vaccine based on its proprietary outer membrane vesicles (OMV) platform technology. Called NGoXIM, the vaccine is based on gonococcal OMVs combined with ...

While the MCC experience highlights the potential indirect effects that can be achieved with meningococcal vaccines, it is not advisable to extrapolate the effects of this vaccine to others ...

In England and Wales, MCC vaccine programs resulted in substantial herd immunity, as shown by reductions in serogroup C carriage prevalence and serogroup C disease in unvaccinated individuals.